Back to top

biotechs: Archive

Zacks Equity Research

Rallybio (RLYB) Sees Hammer Chart Pattern: Time to Buy?

Rallybio (RLYB) has been struggling lately, but the selling pressure may be coming to an end soon.

RLYBNegative Net Change

Zacks Equity Research

Fennec (FENC) Gets CRL From FDA for Pedmark, Stock Down

Fennec (FENC) suffers a setback again with a CRL for its new drug application (NDA) for Pedmark. Shares are down in pre-market trading.

SRPTPositive Net Change VKTXNegative Net Change EDITPositive Net Change FENCNegative Net Change

Zacks Equity Research

Adagene (ADAG) Gets FDA Nod to Begin Solid Tumor Antibody Study

The FDA grants Adagene (ADAG) a clearance to initiate clinical studies of its investigational candidate ADG116 in combination with pembrolizumab to treat advanced/metastatic solid tumors.

MRKPositive Net Change DTILPositive Net Change ISEENegative Net Change ADAGNegative Net Change

Zacks Equity Research

Bristol Myers' (BMY) Plaque Psoriasis Drug Filings Get Through

Bristol Myers' (BMY) applications seeking approval for deucravacitinib are accepted by the regulatory bodies of both the United States and the European Union.

NVSNegative Net Change BMYNegative Net Change AMGNNegative Net Change ABBVNo Net Change

Sweta Jaiswal, FRM

Moderna ETFs Rallying on COVID-19 Vaccine News to Combat Omicron

Moderna has been rallying amid concerns surrounding the omicron variant, which has led to possibilities of a rise in demand for COVID-19 vaccines and boosters.

MRNANegative Net Change IBBNegative Net Change BBHNegative Net Change IDNAPositive Net Change GERMPositive Net Change

Zacks Equity Research

Blueprint Medicines (BPMC) Set to Acquire Lengo Therapeutics

Blueprint Medicines (BPMC) inks an agreement to acquire privately held Lengo Therapeutics. The company is looking to boost its lung cancer portfolio with this acquisition.

SRPTPositive Net Change VTVTNegative Net Change BPMCNegative Net Change EDITPositive Net Change

Zacks Equity Research

Moderna (MRNA) Rallies on Booster Hopes Amid Omicron Concerns

Demand for Moderna's (MRNA) COVID-19 vaccine booster dose might increase if the Omicron variant causes a rise in infection rates.

PFEPositive Net Change MRNANegative Net Change NVAXPositive Net Change BNTXNegative Net Change

Benjamin Rains

Buy This Tech Stock on the Dip Before Earnings for Big Growth?

VEEV is trading nearly 15% below its records heading into its Q3 earnings release that's due out after the closing bell on Wednesday, December 1...

VEEVNegative Net Change

Zacks Equity Research

Omicron Fears Fuel Rally in Vaccine Stocks: Will It Continue?

Another variant of the coronavirus, Omicron, is up on the WHO-identified list. Several mutations of this variant spark fears of high resistance to the COVID-19 vaccines.

PFEPositive Net Change MRNANegative Net Change NVAXPositive Net Change BNTXNegative Net Change

Zacks Equity Research

Deciphera (DCPH) Down More Than 70% in Past 3 Months: Here's Why

Deciphera's (DCPH) sole marketed drug, Qinlock, is approved for treating advanced gastrointestinal stromal tumors. The recent regulatory setback for Qinlock has hurt the stock.

NVSNegative Net Change PFEPositive Net Change BPMCNegative Net Change DCPHPositive Net Change

Zacks Equity Research

Novavax (NVAX) Stock Up YTD on COVID-19 Vaccine Potential

Novavax (NVAX) is likely to generate huge revenues as the company has started filing approvals for emergency use of its COVID-19 vaccine in multiple nations.

GSKNegative Net Change NVAXPositive Net Change DTILPositive Net Change ISEENegative Net Change

Zacks Equity Research

Bristol Myers (BMY) Top Drugs Maintain Momentum Amid Competition

Bristol Myers' (BMY) performance has been good of late, driven by Revlimid, Eliquis, Opdivo and its new product portfolio amid stiff competition.

BMYNegative Net Change MRKPositive Net Change SRPTPositive Net Change VKTXNegative Net Change

Zacks Equity Research

Ligand's (LGND) Drug-Developing Technologies Holds Potential

Ligand's (LGND) Captisol technology is a key driver for its topline. The company plans to spin off another potential technology platform, OmniAb, into a separate company.

NVSNegative Net Change AMGNNegative Net Change GILDNegative Net Change LGNDPositive Net Change

Zacks Equity Research

4 Reasons Why You Should Add Sarepta (SRPT) to Your Portfolio

Sarepta's (SRPT) stock creates a significant opportunity for investors on the back of solid demand for its commercialized drugs and steady progress with its key pipeline candidates.

RHHBYPositive Net Change PFEPositive Net Change SRPTPositive Net Change RGNXPositive Net Change

Zacks Equity Research

Gilead Sciences (GILD) Stock Gains 20% YTD: What Lies Ahead?

Gilead's (GILD) performance in the year has been pretty good on contribution from Veklury. The company is now focusing on its oncology business as the virology business faces challenges.

GSKNegative Net Change GILDNegative Net Change SRPTPositive Net Change RCUSNegative Net Change

Zacks Equity Research

Selecta (SELB) Down on FDA's Clinical Hold on Phase I/II Study

The FDA issues a clinical hold on Selecta's (SELB) phase I/II study evaluating SEL-302 for the treatment of patients with methylmalonic acidemia. Shares down in after-hours trading.

SRPTPositive Net Change VTVTNegative Net Change EDITPositive Net Change SELBPositive Net Change

Zacks Equity Research

Biotech Stock Roundup: Drug Approvals for BMRN, Updates From BIIB, BMY, MRNA & More

Drug approvals for BioMarin (BMRN) and regulatory updates from Biogen (BIIB), among others, have been the biotech sector's few key highlights during the past week.

BIIBPositive Net Change BMYNegative Net Change BMRNNegative Net Change GILDNegative Net Change MRNANegative Net Change

Zacks Equity Research

Amryt (AMYT) Skin Disorder NDA Review Gets 3 Months Extension

Amryt (AMYT) is seeking approval for Oleogel-S10 for treating epidermolysis bullosa, a rare genetic skin disorder, in the United States and Europe. The FDA extends the review period for the drug's NDA to reviewnew data submission.

ISEENegative Net Change IMABNegative Net Change AMYTPositive Net Change INBXPositive Net Change

Zacks Equity Research

Gilead (GILD) Gets EU Nod for Breast Cancer Drug, Trodelvy

The European Commission grants marketing authorization to Gilead's (GILD) Trodelvy as a monotherapy for the second-line treatment of adults with metastatic triple-negative breast cancer.

GSKNegative Net Change MRKPositive Net Change GILDNegative Net Change DTILPositive Net Change

Zacks Equity Research

Bristol Myers (BMY) Zeposia Gets EC Nod for Ulcerative Colitis

Bristol Myers (BMY) wins EC approval for Zeposia for a second indication ??? ulcerative colitis.

BMYNegative Net Change MRKPositive Net Change SRPTPositive Net Change VKTXNegative Net Change

Zacks Equity Research

CRISPR's (CRSP) CAR-T Cell Therapy Gets FDA's RMAT Designation

The FDA grants a Regenerative Medicine Advanced Therapy designation to CRISPR Therapeutics' (CRSP) CTX110 targeting CD19+ B-cell malignancies.

VRTXNegative Net Change EDITPositive Net Change CRSPPositive Net Change DTILPositive Net Change

Zacks Equity Research

Deciphera (DCPH) Gets EU Nod for Qinlock in Fourth-Line GIST

The European Commission approves Deciphera's (DCPH) Qinlock for the treatment of fourth-line gastrointestinal stromal tumor.

NVSNegative Net Change BPMCNegative Net Change EDITPositive Net Change DCPHPositive Net Change

Zacks Equity Research

REGENXBIO (RGNX) DMD Gene Therapy Gets Orphan Drug Status

REGENXBIO (RGNX) is developing a gene therapy candidate, RGX-202, for treating DMD, which is currently in the pre-clinical stage. An IND application is expected by the end of 2021.

SRPTPositive Net Change ABBVNo Net Change RGNXPositive Net Change SLDBNegative Net Change

Zacks Equity Research

bluebird (BLUE) Filing for Thalassemia Therapy Gets Priority Review

bluebird (BLUE) application seeking approval for beti-cel for thalassemia gets priority review in the United States.

BMYNegative Net Change SRPTPositive Net Change BLUENegative Net Change TSVTNegative Net Change

Zacks Equity Research

Mirati (MRTX), Verastem to Study Cancer Drugs for NSCLC

Mirati Therapeutics (MRTX) partners Verastem Oncology (VSTM) to evaluate adagrasib in combination with VS-6766 in KRASG12C-mutant non-small cell lung cancer.

BMYNegative Net Change MRKPositive Net Change MRTXPositive Net Change VSTMPositive Net Change